Cambridge Healthtech Institute’s Second Annual
Adoptive T Cell Therapy
Techniques and Strategies for Cell Therapy Discovery and Development
Part of the 11th Annual PEGS: the essential protein engineering summit
May 6-7, 2015 | World Trade Center | Boston, Massachusetts


Recent advances in protein engineering and molecular biology have increased the feasibility of using genetically engineered T cells to treat disease, leading to an influx of new discoveries and techniques. With these new treatments becoming ready for prime-time, researchers will need to increase their discovery efforts to meet patient need and continue advancing the field. Cambridge Healthtech Institute's Second Annual Adoptive T Cell Therapy will review the latest strategies for target discovery, as well as T cell receptors (TCRs), chimeric antigen receptors (CAR), and tumor infiltrating lymphocytes (TILs) against tumor antigens. This event will focus on issues facing the field with an emphasis on engineered T cells and the use of adoptive t cell transfer to facilitate therapeutic treatments for cancer, infectious diseases, and bone marrow transplants. Clinical data will be showcased as well as in depth examinations of where the field is headed.

Topics may include, but are not limited to: 

  • Adoptive T cell therapy for cancer, HIV, bone marrow transplant, and infectious diseases
  • Techniques and strategies for target selection and discovery
  • Targeting solid tumors
  • Principles of chimeric antigen receptor design
  • Developing optimal fusion proteins
  • Getting your fusion protein into your t cell
  • Choosing vectors for T cell transfusion
  • Selecting relevant domains
  • Creating nucleases to increase specificity
  • Receptor modification with T cells
  • Dosing issues
  • Predicting adverse events in humans
  • Mitigating the potential for toxicity
  • Available tools and technologies

Scientists who wish to present their knowledge and expertise to their colleagues are asked to click here to submit an abstract. Remember to specify the conference that you are interested in and please provide your full contact information.

The deadline for submission is October 3, 2014. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For more details on the conference, please contact:
Samantha Lewis
Conference Producer
Cambridge Healthtech Institute
T: 781-972-5461
E: slewis@healthtech.com 

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452
E: jgerardi@healthtech.com 

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781-972-5471
E: dinerstein@healthtech.com